Identification of a novel variant CYP2C9 allele in Chinese
- 1 July 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 14 (7) , 465-469
- https://doi.org/10.1097/01.fpc.0000114749.08559.e4
Abstract
Cytochrome P450 (CYP) 2C9 metabolizes about 16% of drugs in current clinical use, including lornoxicam and tolbutamide. SNPs in the CYP2C9 gene have increasingly been recognized as determinants of the metabolic phenotype that underlies interindividual and ethnic differences. The present study focused on a Chinese poor metabolizer (PM) whose apparent genotype (CYP2C9*1/CYP2C9*3) did not agree with his PM phenotype for both lornoxicam and tolbutamide. By sequencing his CYP2C9 gene, we identified a new variant CYP2C9 allele involving a T269C transversion in exon 2 that leads to a Leu90Pro substitution in the encoded protein. The CYP2C9 genotype analysis in the family of the poor metabolizer showed the new exon 2 change and CYP2C9*3 occurred on different alleles. Thus, the PM status of this subject could be attributed to his being heterozygous for the CYP2C9 T269C allele together with the CYP2C9*3. Frequency analysis in 147 unrelated Chinese males indicated approximately 2% of the Chinese population carry the allele. This study suggests that this novel CYP2C9 allele was correlated with reduced plasma clearance of drugs that are substrates for CYP2C9.Keywords
This publication has 20 references indexed in Scilit:
- Clinical relevance of genetic polymorphisms in the human CYP2C9 geneEuropean Journal of Clinical Investigation, 2003
- Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populationsFundamental & Clinical Pharmacology, 2003
- Tolbutamide, Flurbiprofen, and Losartan as Probes of CYP2C9 Activity in HumansThe Journal of Clinical Pharmacology, 2003
- Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotesClinical Pharmacology & Therapeutics, 2002
- Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: In vitro and in vivo studiesClinical Pharmacology & Therapeutics, 2001
- Clinical Pharmacokinetics and Pharmacodynamics of CelecoxibClinical Pharmacokinetics, 2000
- Identification of Residues 286 and 289 as Critical for Conferring Substrate Specificity of Human CYP2C9 for Diclofenac and IbuprofenArchives of Biochemistry and Biophysics, 1998
- Cytochrome P4502C9: an enzyme of major importance in human drug metabolismBritish Journal of Clinical Pharmacology, 1998
- Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4Xenobiotica, 1998
- Detection of CYP2C9 polymorphism based on the polymerase chain reaction in ChinesePharmacogenetics, 1995